207 related articles for article (PubMed ID: 11200876)
21. Patient preferences for treatment of rheumatoid arthritis.
Fraenkel L; Bogardus ST; Concato J; Felson DT; Wittink DR
Ann Rheum Dis; 2004 Nov; 63(11):1372-8. PubMed ID: 15020312
[TBL] [Abstract][Full Text] [Related]
22. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
23. [Etanercept (Enbrel)--our experiences].
Morović-Vergles J; Martinović-Kaliterna D
Reumatizam; 2007; 54(2):69-70. PubMed ID: 18351144
[TBL] [Abstract][Full Text] [Related]
24. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
[TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
26. Phlegmonous abscess associated with etanercept therapy.
D'Amore M; Minenna G; Favoino E; D'Amore S
Panminerva Med; 2006 Sep; 48(3):199-200. PubMed ID: 17122757
[No Abstract] [Full Text] [Related]
27. Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept.
Takatori S; Kamata Y; Murosaki T; Iwamoto M; Minota S
J Rheumatol; 2010 Jan; 37(1):210-1. PubMed ID: 20040649
[No Abstract] [Full Text] [Related]
28. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
29. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization.
Quartuccio L; De Re V; Fabris M; Marzotto A; Franzolini N; Gasparotto D; Caggiari L; Ferraccioli G; Scott CA; De Vita S
Haematologica; 2006 May; 91(5):691-4. PubMed ID: 16670074
[TBL] [Abstract][Full Text] [Related]
30. Rheumatoid arthritis.
Emery P; Suarez-Almazor M
Clin Evid; 2003 Jun; (9):1349-71. PubMed ID: 15366179
[No Abstract] [Full Text] [Related]
31. Etanercept-associated right abducens nerve palsy in rheumatoid arthritis.
Lai CC; Hsiao KH; Chang YS; Tsai CY; Chou CT
Int J Rheum Dis; 2012 Oct; 15(5):e117-9. PubMed ID: 23083045
[No Abstract] [Full Text] [Related]
32. Coarctation of the aorta in an infant exposed to etanercept in utero.
Hemmati I; Stephanie E; Shojania K
J Rheumatol; 2009 Dec; 36(12):2848. PubMed ID: 19966200
[No Abstract] [Full Text] [Related]
33. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy.
Kaur PP; Derk CT; Chatterji M; Dehoratius RJ
J Rheumatol; 2004 Aug; 31(8):1663-5. PubMed ID: 15290751
[TBL] [Abstract][Full Text] [Related]
34. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
35. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
Blank N; Max R; Schiller M; Briem S; Lorenz HM
Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
[No Abstract] [Full Text] [Related]
36. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
Yazici Y; Erkan D
Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
[No Abstract] [Full Text] [Related]
37. Rheumatoid arthritis drugs show promise.
Mayo Clin Health Lett; 1999 Jan; 17(1):4. PubMed ID: 9919935
[No Abstract] [Full Text] [Related]
38. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
40. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
